Simvastatin plus rifaximin did not reduce progression to acute-on-chronic liver failure, complications from cirrhosis or risk for death in patients with decompensated cirrhosis, according to data ...
Rifaximin monotherapy reduces risk for breakthrough OHE episode and results in a lower mortality rate than lactulose monotherapy. HealthDay News — For patients with a history of overt hepatic ...
Bausch Health and its gastroenterology business, Salix Pharmaceuticals, has responded to the Food and Drug Administration’s tentative approval of Norwich Pharmaceuticals’ rifaximin 200 mg product, ...
Fewer patients treated with rifaximin had an overt hepatic encephalopathy episode vs. those treated with lactulose (23.2% vs. 49%). Mortality rate also was lower in the rifaximin group (1.6% vs. 4.8%) ...
Most Medicare Part D prescription drug plans and Medicare Advantage plans with drug coverage include rifaximin (Xifaxan) for irritable bowel syndrome with diarrhea (IBS-D) and overt hepatic ...
Mumbai, June 2 -- Rifaximin tablets are indicated for the treatment of irritable bowel syndrome with diarrhoea (IBS-D) in adults. The tablets will be produced at the Group's manufacturing facility at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback